M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers BioPharma DiveEquipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.M&A / DealsImmunology & InflammationRead full story pharminent April 15, 2026 (Last updated: April 16, 2026) BioPharma Dive Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases. M&A / DealsImmunology & InflammationRead full story Post navigation Previous: Travere wins long-awaited approval for kidney disease drugNext: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
